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Coxiella burnetii causes Q fever, a zoonosis, which has acute and chronic manifestations. From 2007 to 2010, the Netherlands
experienced a large Q fever outbreak, which has offered a unique opportunity to analyze chronic Q fever cases. In an observa-
tional cohort study, baseline characteristics and clinical characteristics, as well as mortality, of patients with proven, probable, or
possible chronic Q fever in the Netherlands, were analyzed. In total, 284 chronic Q fever patients were identified, of which 151
(53.7%) had proven, 64 (22.5%) probable, and 69 (24.3%) possible chronic Q fever. Among proven and probable chronic Q fever
patients, vascular infection focus (56.7%) was more prevalent than endocarditis (34.9%). An acute Q fever episode was recalled
by 27.0% of the patients. The all-cause mortality rate was 19.1%, while the chronic Q fever-related mortality rate was 13.0%, with
mortality rates of 9.3% among endocarditis patients and 18% among patients with a vascular focus of infection. Increasing age
(P 0.004 and 0.010), proven chronic Q fever (P 0.020 and 0.002), vascular chronic Q fever (P 0.024 and 0.005), acute pre-
sentation with chronic Q fever (P 0.002 and P< 0.001), and surgical treatment of chronic Q fever (P 0.025 and P< 0.001)
were significantly associated with all-cause mortality and chronic Q fever-related mortality, respectively.
Q fever is a zoonosis caused by the bacterium Coxiella burnetii,which has its main reservoir in small ruminants. Outbreaks
of the disease occur worldwide (1). After primary infection, 50 to
60% of patients remain asymptomatic, while others develop
symptomatic acute Q fever, a flu-like illness, which is mostly self-
limiting (1–3). Between 2007 and 2010, a large outbreak of acute
Q fever was observed in the Netherlands with 4,000 reported
cases (4). These figures are probably rather conservative, as sero-
prevalence studies show that at least40,000 peoplewere infected
by C. burnetii (5).
From previous observations, it is know that chronic Q fever
can develop in approximately 1 to 5% of C. burnetii-infected pa-
tients and mostly manifests itself within the first year after infec-
tion, but the disease can also present itself several years later (1, 6).
The most common manifestations are endocarditis, which ac-
cording to the literature accounts for approximately 75% of all
chronic Q fever cases, and vascular chronic Q fever, consisting of
infections of vascular prostheses and aortic aneurysms (1, 7–9).
Less common manifestations are osteomyelitis, pericarditis, and
hepatitis (8). Important risk factors are heart valve pathology,
especially valve prostheses, vascular prostheses, and aneurysms
(9–12). Immunosuppression also seems to be associated with an
elevated risk, as well as older age, pregnancy, and (mild) renal
insufficiency (3, 11, 12). Before severe complications occur, most
patients are asymptomatic or report only nonspecific symptoms
such as low-grade fever, night sweats, and weight loss (1, 6, 9, 13).
In case of endocarditis, findings on echocardiography are often
nonspecific or absent (13). An early diagnosis of chronic Q fever
has major clinical implications, as chronic Q fever causes high
morbidity and a mortality rate of up to 60% when left untreated
(1, 13). Long-term antibiotic treatment, consisting of doxycycline
and hydroxychloroquine, and resection of infected vascular and
valvular tissue are thought to improve prognosis (9, 13, 14).
Unfortunately, diagnosing chronic Q fever has proven to be
challenging. A positive PCR or culture of C. burnetii in blood or
tissue, in the absence of a serologic profile for acute Q fever, is
considered diagnostic for chronic Q fever. However, PCR on
blood has a limited sensitivity of only 50 to 60% (15–17). There-
fore, serological analysis has an essential role in the diagnosis of
chronic Q fever. C. burnetii exhibits antigenic variation when it is
cultured in cells, as the virulent organisms producing phase I an-
tigen shift to avirulent organisms producing phase II antigen.
Chronic Q fever is characterized by persistent high titers of IgG
antibodies againstC. burnetii phase I antigens (phase I IgG) (3). A
phase I IgG cutoff titer of 800, based on an in-house-developed
immunofluorescence assay (IFA), as well as a cutoff titer of 1,024
based on a commercially available IFA (Focus Diagnostics) have
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been used as standards for the serological diagnosis of chronic Q
fever (15, 18–20). Recent studies show that serology alone, in the
absence of PCR positivity, is not sufficient for the diagnosis of
chronic Q fever and should therefore be combined with clinical
data (21). The Dutch consensus group for the diagnosis of Q fever
proposed to categorize patients into proven, probable, or possible
chronic Q fever. This classification ranks the probability of having
chronic Q fever based on PCR, serology, clinical parameters, im-
aging studies, and pathology (Table 1) (15).
To gain more insight into the chronic consequences and long-
term prognosis of infection with C. burnetii after the recent out-
break in the Netherlands, the initiative called the Dutch National
Chronic Q Fever Database was started. This is a joint effort of
multiple hospitals of the Q fever-afflicted areas to monitor and
assess all chronic Q fever cases in the Netherlands. Five years after
the start of the Q fever epidemic, we present data generated from
this initiative, which is one of the largest cohorts of chronicQ fever
patients in the world, with special emphasis on chronic Q fever
mortality.
MATERIALS AND METHODS
DutchNationalChronicQFeverDatabase.AllDutch hospitals that treat
chronic Q fever patients were actively approached to include in the data-
base chronic Q fever patients who were detected since the start of the
DutchQ fever epidemic in 2007.Most of the hospitals were situated in the
epidemic region, the southwest of the Netherlands, in which the majority
(95%) of the patients were treated. The other patients were treated in
numerous hospitals situated in regions where the epidemic did not occur.
Design of the database and the use of the collected information for anal-
ysis and scientific publications were approved by the Medical Research
Ethics Committee of the University Medical Centre Utrecht. In the cur-
rent study, we used information about patients included in this database
until the end of May 2012.
Patients. Patients were included in the database if they were 18 years
old or older and they fulfilled the criteria of proven, probable, or possible
chronic Q fever according to the recent Dutch consensus guideline (Table
1) (15). In this guideline, the proven chronic Q fever group represents
patients with the most definite form of chronic Q fever, in contrast to the
possible chronic Q fever group, which represents patients with serology
indicating chronic Q fever but without other manifestations of chronic
disease. For the analysis of mortality of chronic Q fever patients, we chose
to include only the patients with proven and probable chronic Q fever, as
most likely a certain number of possible chronic Q fever patients do not
have actual chronic Q fever. For deceased patients, we assessed the cause
of death and whether mortality was due to chronic Q fever. Some of these
patients died of diseases not related to chronicQ fever (e.g., malignancies)
or it could not be determined whether death was due or related to chronic
Q fever (e.g., malaise, sepsis). Death association with chronic Q fever was
defined by one researcher (L.M.K.) as definitely (caused by vascular com-
plications, endocarditis), probably (caused by heart failure in case of sus-
pected endocarditis, gastrointestinal bleeding in case of suspected arteri-
ointestinal fistula, clinical deterioration in case of antibiotic refusal, or
severe side effects ofmedication), possibly (coincidingwith severe comor-
bidities or unknown cause of mortality) or not associated (other cause of
mortality, such as cancer).
Data collection and storage.Data on patient characteristics, imaging
results, laboratory results, antibiotic therapy, and outcome were collected
from patient records provided by the hospitals that participated in the
database. All data were stored and processed anonymously in SPSS ver-
sion 18 (SPSS, Inc., Chicago, IL).
Microbiological analysis. In the Netherlands, routine microbiologi-
cal work-up for the diagnosis of chronicQ fever consists of serology, using
an indirect fluorescent-antibody assay (IFA) (FocusDiagnostics, Inc., Cy-
press, CA) and PCR for C. burnetii DNA on plasma or serum and, if
available, tissue. Titration of antibody levels was carried out at the differ-
ent hospital sites with dilutions according to a binary scale and a detection
cutoff titer of 32. Some hospitals performed complement binding reac-
tions (CBR), also referred to as complement fixation (CF) tests, for the
diagnosis and follow-up of chronic Q fever. However, in all but three
patients CBR results were at least, at one time point, confirmed with IFA.
PCR for C. burnetii DNA was performed using an in-house assay as pre-
viously described (22). An input volume of 500 l plasma or serum was
used for DNA isolation.
Statistical methods. We used descriptive statistics to present data on
baseline and clinical characteristics. In univariate analyses, patient char-
acteristics were related to mortality using the log-rank test. Analyses were
conducted separately for all-cause mortality and chronic Q fever-related
mortality, the latter defined as death definitely or probably caused by
chronic Q fever. Risk factors that were significantly andmostly associated
with mortality in univariate analysis were additionally evaluated using
multivariable Cox regression analysis. Due to multicollinearity and the
limited number of deceased subjects, we could not include all risk factors
simultaneously. The multivariable analyses were also conducted for all-
cause mortality and chronic Q fever-related mortality separately in two
models. Given the limited number of deceased subjects, only univariate
evaluation was used for variables that applied to only part of the popula-
tion (e.g., characteristics of acute Q fever episodes and surgical treat-
ment). Differences were considered significant at P values of0.05.
TABLE 1 Dutch consensus guidelines on chronic Q fever diagnosisa
Diagnosis Characteristicsb
Proven chronic Q fever Positive Coxiella burnetii PCR in blood or tissuec OR an IFA titer of800 or 1,024 for C. burnetii phase I IgGd with
either definite endocarditis according to the modified Duke criteria (19) or proven large vessel or prosthetic infection
by imaging studies (FDG-PET [18], CT, MRI, or AUS)
Probable chronic Q fever IFA titer of800 or 1,024 for C. burnetii phase I IgGc AND valvulopathy not meeting the major criteria of the modified
Duke criteria (19) OR known aneurysm and/or vascular or cardiac valve prosthesis without signs of infection by
imaging studies (TEE/TTE, FDG-PET [18], CT, MRI, or AUS) OR suspected osteomyelitis, pericarditis, or hepatitis
as manifestations of chronic Q fever OR pregnancy OR symptoms and signs of chronic infection such as fever,
weight loss, night sweats, hepatosplenomegaly, and persistent raised ESR and CRP OR granulomatous tissue
inflammation as proven by histological examination OR immunocompromised state
Possible chronic Q fever IFA titer of800 or 1,024 for C. burnetii phase I IgGd without manifestations meeting the criteria for proven or
probable chronic Q fever
a See reference 15.
b IFA, immunofluorescence assay; FDG-PET, fluorodeoxyglucose positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; AUS, abdominal
ultrasound; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
c In the absence of acute infection.
d Cutoff is dependent on the IFA technique used (developed in-house or a commercial IFA technique, respectively).
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RESULTS
In total, 284 patients were included in the chronic Q fever data-
base. Of these, 151 patients (53.7%) had proven chronic Q fever,
64 patients (22.5%) probable chronic Q fever, and 69 patients
(24.3%) possible chronic Q fever. Baseline characteristics and de-
tails of chronic and acute Q fever episodes of these patients are
shown in Table 2. Microbiology results of all chronic Q fever pa-
tients are presented in Table 3.
The overall mortality rate among chronic Q fever patients was
15.8%, of which 23.2% comprised proven cases, 9.4% comprised
probable cases, and 5.8% comprised possible cases. Of the 215
patients with proven or probable chronicQ fever, 41 (19.1%) died
during amedian follow-up of 14.3months (interquartile range 25
to 75% [10.1 to 23.1 months]). Mortality definitely or probably
associated with chronic Q fever among patients with proven or
probable chronic Q fever was 13.0% (28/215 patients), with a
9.3% mortality rate among endocarditis patients, and 18.0% in
patients with a vascular focus of infection. The causes of mortality
TABLE 2 Baseline and clinical characteristics of chronic Q fever cases in the Netherlands
Characteristica
All chronic Q fever
(n 284)
Proven chronic Q
fever (n 151)
Probable chronic Q
fever (n 64)
Possible chronic Q
fever (n 69)
Male (n [%]) 204 (71.6) 115 (76) 48 (75) 41 (59)
Age (mean [SD]) (yr) 64.9 (14.1) 68.6 (12) 65.2 (15) 56.6 (15)
Focus of infectionb (n [%])
Endocarditis 75 (26.4) 49 (32) 26 (41)
Infection of valve prosthesis 38 (13.3) 31 (21) 7 (11)
Vascular infection 122 (42.0) 104 (69) 18 (28)
Infection of vascular prosthesis 57 (20.1) 45 (30) 12 (19)
Other focus (n [%]) 6 (2.1) 2 (1)i 4 (76)l
No focus (n [%]) 92 (33.1) 7 (5)j 16 (25)m 69 (100)
Known acute Q fever episode (n [%]) 106 (37.3) 28 (19)k 30 (47) 48 (70)
Adequate treatmentc,d 81 (76) 19 (68) 24 (80) 38 (79)
Echocardiogram (TEE or TTE) performedd 21 (20) 8 (29) 3 (10) 10 (21)
Imaging of abdominal aorta by AUSd 14 (13) 5 (18) 4 (13) 5 (10)
Risk factor for chronic Q feverd 34 (32) 17 (61) 15 (50) 2 (4)
Chronic Q fever prophylaxisd,e 4 (4) 4 (14)
Risk factors for chronic Q fever (n [%]) 152 (53.5) 107 (71) 42 (66) 3 (4)
History of valvulopathy 68 (23.9) 48 (32) 19 (30) 1 (1)
Valve prosthesis or plasty 45 (15.8) 36 (24) 9 (14)
History of aneurysm 28 (9.9) 22 (15) 6 (9)
History of vascular prosthesis 61 (21.5) 49 (32) 12 (19)
Immunosuppressionf 19 (6.7) 11 (7) 8 (13)
Pregnancy during acute episode 5 (1.8) 1 (1) 2 (3) 2 (3)
Surgical treatment due to Q fever (n [%]) 65 (22.9) 64 (42) 1 (2)
Valve surgeryg 13 (4.6) 12 (8) 1 (2)
Vascular surgeryg 53 (19.0) 54 (36)
Deceasedh (n [%]) 45 (15.8) 35 (23) 6 (9) 4 (6)
No. of deceased patients with endocarditis/total no. of patients
with endocarditis (%)
12/75 (16) 10/49 (20) 2/24 (8) NAn
No. of deceased patients with vascular infection/total no. of
patients with vascular infection (%)
28/122 (23) 26/104 (25) 2/18 (11) NA
Definitely or probably deceased due to chronic Q fever (n [%]) 28 (9.8) 27 (18) 1 (2)
a TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; AUS, abdominal ultrasound.
b In 11 proven chronic Q fever patients, imaging studies revealed that the focus of infection could be both on the heart valves and vascular structures.
c Proven effective antibiotic treatment regime for at least 10 days.
d Percentages estimated for all chronic cases with an acute Q fever episode only.
e Doxycycline and hydroxychloroquine for at least 6 months.
f Prednisone cumulative dose750 mg, tumor necrosis factor alpha (TNF-)-blocker usage, methotrexate usage, mycophenolate mofetil usage, splenectomy, hematologic
malignancies.
g Two patients underwent both vascular and heart valve surgery, one patient underwent replacement of thoracic aneurysm and aortic valve and one patient underwent replacement
of aortic valve and vascular surgery of an aneurysm of the left arteria iliaca.
h In two deceased patients with proven chronic Q fever, the focus of infection could have been both on heart valves and vascular structures.
i One patient with pericarditis and one patient with an infected placenta (confirmed by PCR).
j All had positive PCR results for blood samples; six patients had cardiovascular risk factors, and two were immunocompromised.
k Data missing in seven patients.
l One patient with pericarditis, two patients with chronic serologic profiles during pregnancy, and one patient with spondylodiscitis.
m Six patients with clinical signs of systemic infection, 10 patients with immunocompromised status.
n NA, not applicable.
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of the proven and probable chronicQ fever cases are shown in Fig.
1. Figure 2 presents a Kaplan-Meier survival curve based on the
multivariable model. Of the deceased patients with chronic Q fe-
ver, 50% died upon presentation or within the first 4months after
diagnosis.
In Table 4, clinical characteristics of all proven and probable
chronic Q fever patients who died (n  41) are compared with
those of patients who did not die (n 174). The group of deceased
patients was analyzed as an all-causemortality group (n 41) and
as a group with chronic Q fever-related mortality (n  28). In-
creasing age (P 0.004 and 0.010), proven chronic Q fever (P
0.020 and 0.002), vascular infection as the focus of chronicQ fever
(P  0.024 and 0.005), acute presentation with chronic Q fever
(P  0.002 and P  0.001), and surgical treatment of chronic Q
fever (P 0.025 and P 0.001) were significantly associated with
all-cause mortality and chronic Q fever-related mortality, respec-
tively. Analysis of only those patients who underwent surgical in-
tervention demonstrated that emergency surgical treatment in
particular was associated with mortality (P  0.007 for all-cause
mortality and 0.017 for chronic Q fever-related mortality).
In multivariable Cox regression analysis, age (hazard ratio
[HR] 1.57; 95% confidence interval [CI] 1.13 to 2.19 per 10-year
increase of age) and acute presentation with chronic Q fever (HR,
1.96; 95% CI, 1.02 to 3.78) were independent predictors of all-
cause mortality (Table 5). Age was also an independent predictor
of chronic Q fever related-mortality (HR, 1.59; 95% CI, 1.14 to
2.21 per 10-year increase of age).
DISCUSSION
Until the end of May 2012, 284 patients with proven, probable, or
possible chronic Q fever were identified in the Dutch National
Chronic Q Fever Database. Of all chronic Q fever cases, 108 pa-
tients (38.0%) recalled an acute Q fever episode, although among
proven and probable cases, only 58 patients (27.0%) had a known
acute Q fever episode. During the Q fever epidemic, over 4,000
cases of acute Q fever were reported (4). Therefore, the risk for
chronic Q fever development after a symptomatic acute Q fever
episode is approximately 2.5% if all chronicQ fever cases are taken
into account, and 1.5% if limited only to proven and probable
chronic Q fever cases. These figures are in line with the previously
reported rate of 1 to 5% (1, 6). However, based on seroprevalence
studies, estimates of the total number of C. burnetii infections in
the Dutch outbreak are up to 10-fold higher than the number of
reported cases (5, 23). Extrapolating these data, the number of
identified chronic Q fever patients in the Netherlands does not
reach this rate of 1 to 5% of C. burnetii infections by far (1). This
could indicate that the majority of chronic Q fever cases are still
undetected, although this is less likely as it is more than 2 years
after the end of the Q fever epidemic and it has been shown that
most chronic Q fever cases manifest themselves in the first year
after infection (1, 6). It could also indicate that in the Dutch out-
break the percentage of C. burnetii-infected patients who eventu-
ally developed chronic Q fever was lower than previously re-
ported.
Themajority of chronic Q fever patients did not recall an acute
Q fever episode, an exception being patients with possible chronic
Q fever (69.6%), whoweremostly detected in follow-up programs
after a recognized acuteQ fever episode. This could be due to a low
detection rate of acute Q fever cases, or to overlap with other
febrile diseases, especially in the beginning of the epidemic. It
could also indicate that asymptomatic primary infections also
bring about the risk for development of chronic Q fever, maybe
even more so than symptomatic infections. Therefore, early de-
tection of chronic Q fever might not be accomplished only by
follow-up programs of recognized acute Q fever cases; screening
of high-risk groups after an acute Q fever outbreak should also be
prioritized.
Notably, among the proven and probable chronic Q fever pa-
tients in the Netherlands, we found more patients with a vascular
focus of infection (56.7%) than patients with endocarditis
(35.3%). This is in contrast with earlier reports from France,
where endocarditis predominates (1, 7). It might be that this dis-
parity is caused by strain-specific differences, leading to distinct
clinical presentations (24). Another explanation might be in-
creased awareness in the Netherlands of this previously relatively
unacknowledgedmanifestation of chronic Q fever. In 11 patients,
imaging studies revealed that the focus of infection could be both
on the heart valves and vascular structures, which was confirmed
in one deceased patient at autopsy, where both the aortic valve as
well as an aneurysm were found to be C. burnetiiDNA positive by
PCR. We found nine proven chronic Q fever patients with a pos-
FIG 1 Causes of death of deceased proven and probable chronic Q fever
patients. Other causes of death weremalignancies, renal failure, and sepsis due
to another pathogenwhichwas unrelated to endocarditis or vascular infection.
TABLE 3 Results of microbiology tests (PCR and IFAa) of all proven,
probable, and possible chronic Q fever patients
Result
All
chronic Q
fever
(n 284)
(n [%])
Proven
chronic Q
fever
(n 151)b
(n [%])
Probable
chronic
Q fever
(n 64)d
(n [%])
Possible
chronic
Q fever
(n 69)
(n [%])
PCR positive in blood only 60 (21.1) 60 (40)
PCR positive in tissue only 25 (8.8) 25 (17)
PCR positive in blood and tissue 35 (12.3) 35 (23)
Phase I IgG titer
512 2 (0.7) 2c (1)
1,024 35 (12.3) 6 (4) 13 (20) 16 (23)
2,048 61 (21.5) 24 (16) 13 (20) 24 (35)
4,096 62 (21.8) 28 (19) 17 (27) 17 (25)
8,192 36 (12.7) 17 (11) 10 (16) 9 (13)
8,192 79 (27.8) 66 (44) 10 (6) 3 (4)
a IFA, immunofluorescence assay.
b For two patients, no titration for a titer above 4,096 was performed; for three patients,
no reliable IFA titer results were obtained due to blood transfusion or fluid
supplementation; for three patients, no IFA titer was performed (PCR results in blood
and/or tissue were positive), but complement binding reaction (CBR) was performed
(PCR results in blood and/or tissue were positive).
c One patient with positive PCR for blood, one patient with positive PCR for vascular tissue.
d In one patient no titration of serology above 4,096 was performed.
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itive PCR result for blood samples who did not have a clear vas-
cular infection or endocarditis. One of these patients had signs of
a pericarditis, while another patient had serologic results consis-
tent with chronic Q fever during pregnancy and a positive C. bur-
netii PCR of placental tissue. In seven patients, no infection focus
was found, despite thorough work-ups with echocardiography
and fluorodeoxyglucose positron emission tomography-com-
puted tomography. Six of these patients had risk factors for car-
diovascular disease and two were immunocompromised (one pa-
tient with acute lymphatic leukemia and one patient on long-term
prednisone therapy).
Recognized risk factors for chronic Q fever development were
present in the majority of patients (53.5% of all cases, 69.3% in
proven and probable cases), except for patients with possible
chronic Q fever infection (4.3%), in whom risk factors consisted
of minor valvulopathies only. In a significant number of proven
and probable chronic Q fever patients, risk factors were not rec-
ognized before presentation. More than half of the patients with
proven vascular chronic Q fever had no history of vascular anom-
alies beforehand. These patients presented at the hospital with
aneurysms, for which in various instances emergency vascular
surgery was needed. Although the role of echocardiography after
an acute Q fever episode remains controversial and requires fur-
ther evaluation (13, 25, 26), screening for an aortic aneurysmwith
abdominal ultrasound at the time of acute Q fever presentation
could result in detection at an early stage of patients at risk for
vascular chronic Q fever. Therefore, we advise to screen for aortic
aneurysms in case of acute Q fever, especially when risk factors for
vascular disease are present, like diabetes mellitus, hypertension,
smoking, dyslipidemia, or positive family history for vascular dis-
ease. Moreover, active case finding in a Q fever epidemic area
could be initiated by screening for Q fever in high-risk groups,
including patients with aneurysms, vascular prostheses, or heart
valve prostheses (12). In our current analysis, minor heart valve
lesions (for example, grade I aortic valve insufficiency) were also
included as risk factors for chronicQ fever, although the influence
of minor valvulopathies on chronic Q fever development is de-
bated (13, 24, 25). This could have led to overestimation of the
amount of risk factors in all chronic Q fever cases.
Overall mortality in chronic Q fever patients was 15.8%. Mor-
tality was highest in patients with proven chronic Q fever (23.2%)
compared to patients with probable chronic Q fever (9.4%) and
possible chronic Q fever (5.8%). As possible chronic Q fever cases
most likely represent, at least in part, patients who do not have
actual chronic Q fever, we omitted them from the analysis of
chronic Q fever mortality. In total, we identified 215 patients with
proven or probable chronic Q fever (among whom all-causemor-
tality was 19.1%) during a median follow-up of 14.3 months (in-
terquartile range, 25 to 75% [10.1 to 23.1 months]). When only
patients with chronic Q fever-relatedmortality were analyzed, the
mortality rate among patients with proven and probable chronic
Q fever was 13.0%, with a 9.3%mortality rate among endocarditis
patients and 18.0% in vascular chronicQ fever cases. These figures
confirm the results of previous studies showing differences in
mortality rates of both disease entities (9, 13, 14). Most patients
died due to vascular complications of vascular chronic Q fever.
Mortality was highest in the first months after the diagnosis of
chronicQ fever. Therewere no significant differences in antibiotic
treatment among deceased and nondeceased patients. Although
all patients were offered treatment, only 83% received adequate
FIG 2 Kaplan-Meier survival curve for proven and probable chronic Q fever patients.
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antibiotic treatment, as some patients refused therapy, while oth-
ers died before treatment could be initiated. As illustrated in Fig. 1,
two patients probably died due to severe side effects of the medi-
cation, consisting of kidney insufficiency and gastrointestinal side
effects. Not unexpectedly, in multivariable analysis, older age was
significantly associated with death in both the all-cause mortality
and chronic Q fever-related mortality groups. Moreover, acute
presentations with chronic Q fever (e.g., symptomatic aneurysm
or severe endocarditis) were significantly associated with all-cause
mortality. Although in univariate analysis proven chronicQ fever,
surgical treatment of chronic Q fever, and vascular focus of infec-
tion were also significantly associated with all-cause and Q fever-
relatedmortality, this was not confirmed inmultivariable analysis.
However, the number of deceased patients was relatively small for
the performance of reliable multivariable analysis. Moreover,
therewere correlations between the included variables. Analysis of
the data showed that the elevatedmortality risk in cases of surgical
intervention was caused by the necessity of emergency surgical
procedures for patients who presented with acute complications
of chronic Q fever, especially in case of vascular infections, and to
a lesser extent endocarditis.
In conclusion, the data of the Dutch National Chronic Q Fever
Database demonstrate that vascular chronic Q fever is a more
common manifestation than Q fever endocarditis in the Nether-
lands.Most patients with chronicQ fever did not recall an episode
of acute Q fever. Chronic Q fever is a severe infection with an
overall high mortality rate. In particular, older patients with vas-
cular infections who present with acute (vascular) complications
needing urgent surgical intervention are at risk of death due to
chronic Q fever. Measures to reduce mortality and morbidity of
chronic Q fever should be directed at early case finding. This can
be achieved through the screening of high-risk groups in case of a
TABLE 4 Characteristics of deceased and nondeceased patients with proven and probable chronic Q fever
Characteristic
Nondeceased
(n 174)
Deceased
(n 41) Pe
Definitely or probably
deceased due to
chronic Q fever
(n 28) Pe
Male (n [%]) 133 (76) 30 (73) 0.67 21 (75) 0.83
Age (mean [SD]) (yr) 66.5 (13) 72.1 (12) 0.004 72.5 (13) 0.010
Risk factor for chronic Q fever (n [%]) 119 (68) 30 (73) 0.40 20 (71) 0.62
Proven chronic Q fever (n [%]) 116 (67) 35 (85) 0.020 27 (96) 0.002
Endocarditis (n [%]) 63 (36) 12 (29) 0.28 7 (25) 0.21
Valve prosthesis or plasty 31 (18) 7 (17) 0.92 4 (14) 0.70
Vascular infection (n [%]) 94 (54) 28 (68) 0.024 22 (79) 0.005
Vascular prosthesis 50 (29) 7 (17) 0.36 4 (14) 0.25
Other focus (n [%]) 6 (3) 0 0.19 0 0.28
No focus (n [%]) 20 (11) 3 (10) 0.31 0 0.05
Acute presentation with chronic Q fever (n [%]) 35 (20) 18 (44) 0.002 16 (57) 0.001
Acute Q fever episode (n [%]) 45 (26) 13 (32) 0.77 8 (29) 0.66
Adequately treated with antibioticsa,b 34 (76) 9 (69) 0.91 4 (50) 0.27
Risk factor for chronic Q feverb 22 (50) 10 (77) 0.076 6 (75) 0.18
Prophylactic therapyb,c 2 (9) 1 (10) 0.79 0 0.47
Adequate antibiotic treatment of chronic Q fever (n [%]) 145 (83) 35 (85) 0.96 23 (82) 0.69
Surgical treatment of chronic Q fever (n [%]) 49 (28) 19 (46) 0.025 17 (61) 0.001
Emergency surgical treatmentd 21 (43) 15 (79) 0.006 13 (76) 0.013
a Proven effective antibiotic treatment regime for at least 10 days.
b Percentages and P values estimated on all chronic cases with an acute Q fever episode only.
c Doxycycline and hydroxychloroquine for at least 6 months.
d Percentages and P values estimated on all chronic cases who underwent surgical treatment only.
e P values estimated with log-rank test.
TABLE 5 Adjusted risk factors for mortality among patients with
proven and probable chronic Q fever
Multivariable model with risk
factors includeda
All-cause mortality
(HR [95% CI])b
Mortality
definitely or
probably due to
chronic Q fever
(HR [95% CI])
Model 1
Age in 10 yr (continuous) 1.57 (1.13–2.19) 1.68 (1.09–2.59)
Proven chronic Q fever 1.63 (0.62–4.26) 5.65 (0.71–44.82)
Vascular infection 1.48 (0.73–2.99) 1.81(0.71–4.59)
Acute presentation with chronic
Q fever
1.96 (1.02–3.78) 2.75 (1.27–5.95)
Model 2
Age in 10 yr (continuous) 1.59 (1.14–2.21) 1.71 (1.11–2.62)
Proven Q fever 1.84 (0.71–4.76) 6.66 (0.84–52.59)
Vascular infection 1.34 (0.63–2.85) 1.46 (0.53–3.99)
Surgical treatment of chronic
Q fever
1.51 (0.75–3.04) 2.09 (0.89–4.89)
a Two multivariable models were constructed because of multicollinearity between
acute presentation with chronic Q fever and surgical treatment of chronic Q fever.
Model 1 includes acute presentation with chronic Q fever and model 2 surgical
treatment of chronic Q fever.
b HR, hazard ratio; 95% CI, 95% confidence interval.
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Q fever epidemic and surveillance for risk factors of chronic Q
fever.
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